BioAtla (BCAB) Expected to Release Earnings on Thursday

BioAtla (NASDAQ:BCAB) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect BioAtla to announce earnings of ($8.50) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB) last announced its earnings results on Friday, May 15th. The company reported ($4.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($10.00) by $5.78.

BioAtla Stock Down 8.8%

BCAB opened at $3.22 on Thursday. BioAtla has a 52 week low of $3.12 and a 52 week high of $71.50. The business has a fifty day simple moving average of $3.72 and a 200-day simple moving average of $6.86. The firm has a market cap of $5.35 million, a P/E ratio of -0.08 and a beta of 0.76.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wall Street Zen raised BioAtla to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $200.00.

Institutional Trading of BioAtla

Several hedge funds have recently modified their holdings of BCAB. Woodline Partners LP purchased a new stake in shares of BioAtla during the first quarter worth approximately $26,000. ADAR1 Capital Management LLC acquired a new stake in shares of BioAtla in the 4th quarter valued at $104,000. Susquehanna International Group LLP raised its holdings in shares of BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of BioAtla during the 3rd quarter worth $235,000. Finally, Jane Street Group LLC lifted its position in shares of BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares during the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical?stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti?tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.